Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NSD2 | O96028 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486861 | 0.82 | NSD2 (0.59) | ALDH1A1NSD2LMNACNR1SMN1; SMN2 | |
| SCHEMBL30714250 | 0.81 | SMN1; SMN2 (0.48) | ALDH1A1NSD2LMNATP53CNR1 | |
| SCHEMBL30714118 | 0.80 | SMN1; SMN2 (0.49) | ALDH1A1NSD2LMNATP53SMN1; SMN2 | |
| SCHEMBL31370874 | 0.80 | SMN1; SMN2 (0.49) | ALDH1A1NSD2LMNATP53SMN1; SMN2 | |
| SCHEMBL4662757 | 0.80 | CA9 (0.50) | LMNACNR2CA1CA2CA7 | |
| SCHEMBL25408197 | 0.79 | CNR1 (0.48) | ALDH1A1NSD2LMNATP53CNR1 | |
| SCHEMBL3914871 | 0.78 | ALDH1A1 (0.76) | ALDH1A1LMNASMN1; SMN2MAPTCYP19A1 | |
| SCHEMBL5960118 | 0.78 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2881016 | 0.78 | ALDH1A1 (0.64) | ALDH1A1TP53SMN1; SMN2MAPTCA1 | |
| SCHEMBL18555031 | 0.77 | CNR1 (0.51) | ALDH1A1NSD2LMNACNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069648-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-03-05 | — | — | US | disclosed |
| US-20200069648-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-03-05 | — | — | US | disclosed |
| CN-110709385-A | Haloallylamine pyrazole derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2018157190-A9 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018157190-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069648-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | LOX, DAO, AADAC | ALDH1A1 301/4885NSD2 1933/4885LMNA 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.